NIFUROXAZIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H9N3O5
Molecular Weight	275.217
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

SMILES

OC1=CC=C(C=C1)C(=O)N\N=C\C2=CC=C(O2)[N+]([O-])=O

InChI

InChIKey=YCWSUKQGVSGXJO-NTUHNPAUSA-N

InChI=1S/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17)/b13-7+

HIDE SMILES / InChI

Description

Nifuroxazide is a nitrofuran antibiotic used for the treatment of acute infectious diarrhoea.Nifuroxazide is a potent inhibitor of Signal transducers and activators of transcription (STAT) signaling. It exerts antineoplastic potential both in vitro and in vivo.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Signal transducer and activator of transcription 3 10	Inhibitor 8,504		3.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 609	Primary		Preclinical	Unknown
Infectious diarrhea 8	Curative		Approved 8,583	ERCEFURYL

Doses

Show entries

Dose	Population	Adverse events
400 mg 3 times / day multiple, oral Studied dose	unhealthy, ADULT	Other AEs: Nausea, Vomiting...

Showing 1 to 1 of 1 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Fever	10%	400 mg 3 times / day multiple, oral Studied dose	unhealthy, ADULT
Neutropenia	10%	400 mg 3 times / day multiple, oral Studied dose	unhealthy, ADULT
Rash	10%	400 mg 3 times / day multiple, oral Studied dose	unhealthy, ADULT
Transaminases increased	10%	400 mg 3 times / day multiple, oral Studied dose	unhealthy, ADULT
Abdominal cramps	20%	400 mg 3 times / day multiple, oral Studied dose	unhealthy, ADULT

Showing 1 to 5 of 8 entries

Previous1 2Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1,087 inhibitor 2,252	inhibitor 2,438	inhibitor 2,507	substrate 9

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP19A1 429 CYP2C19 2,057 CYP1A2 2,153 BCRP 910 P-gp 1,741	P-gp 2,052

Drug as perpetrator

Show entries

Target	Modality	Activity
CYP2C19 2,141	inhibitor 4,027	inconclusive [IC50 3.0901 uM]
CYP2C9 2,497	inhibitor 4,027	inconclusive [IC50 30.9008 uM]
BCRP 985	inhibitor 4,027	no
CYP3A4 2,633	inducer 1,966	no
MRP1 232	activator 342	no

Showing 1 to 5 of 10 entries

Previous1 2Next

Drug as victim

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2,052	substrate 4,014	inconclusive

Showing 1 to 1 of 1 entries

Previous1Next

Tox targets

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2,263	substrate 9

Showing 1 to 1 of 1 entries

Previous1Next

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

200 mg nifuroxazide 4 times a day in 2 to 4 doses.

Route of Administration: Oral

In Vitro Use Guide

2.5-20 uM nifuroxazide induces breast cancer cell apoptosis in a concentration-dependent manner.

Show entries

Name

Type

Language

NSC-759261

Preferred Name

English

NIFUROXAZIDE

Official Name

English

NIFUROXAZIDE [EP IMPURITY]

Common Name

English

NIFUROXAZIDE [MART.]

Common Name

English

Nifuroxazide [WHO-DD]

Common Name

English

Showing 1 to 5 of 10 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Other intestinal antiinfectives

WHO-VATC

QA07AX03

Other intestinal antiinfectives

WHO-ATC

A07AX03

Anti-Infective Agent

NCI_THESAURUS

C28394

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Code System

Code

Type

Description

FDA UNII

PM5LI0P38J

PRIMARY

DRUG BANK

DB13855

PRIMARY

CAS

965-52-6

PRIMARY

RXCUI

31782

PRIMARY

RxNorm

ECHA (EC/EINECS)

213-522-0

PRIMARY

Showing 1 to 5 of 17 entries

Previous1 2 3 4Next

ACTIVE MOIETY


					PM5LI0P38J

NIFUROXAZIDE

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Patents

Sample Use Guides

Drug as perpetrator